Duke University Keeping an Eye on DTC Genomics Firms that Might be Infringing its APOE Patents | GenomeWeb

By Turna Ray

23andMe's new report on Alzheimer's disease risk has raised some eyebrows at Duke University regarding the fact that the direct-to-consumer genomics firm is testing customers for APOE variants without a sublicense for patents on testing methods held by the university and licensed to Athena Diagnostics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.